Weight Loss Drugs
GLP-1 receptor agonists, drugs originally developed for diabetes, have become the biggest pharmaceutical story in decades. They don't just cause weight loss; they appear to reduce heart attacks, treat addiction, and may slow ageing. The market could reach $150B by 2030.
Makes Mounjaro and Zepbound (tirzepatide), currently the most effective GLP-1 drugs available. Has a manufacturing head start and a pipeline of next-generation weight loss treatments that could be taken as pills.
Invented the GLP-1 drug class. Makes Ozempic and Wegovy (semaglutide), the drugs that started the conversation. The original and dominant player, though facing stiff competition from Lilly.
Scores 9/10 for Diabetes Management.
Scores 9/10 for Diabetes Management. Also relevant to Continuous Glucose Monitoring.
Want to explore how these companies connect to each other?